Overview

ImStem is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of regenerative and cellular therapies for patients suffering from serious diseases with significant unmet needs where there are a lack of available treatment options.

ImStem aspires to revolutionize how serious diseases are treated with its new generation of regenerative and cellular therapies. Its first-in-class human Embryonic Stem Cell (hESC)-derived T-MSC investigational cellular therapy is differentiated from hESC via a trophoblast-like stage using ImStem's two-step differentiation technology. ImStem’s pioneering research led to the proprietary state-of-the-art pluripotent stem cell technology, enabling off-the-shelf, allogeneic stem cell-derived products to be mass produced and differentiating itself from the typical challenges imposed by autologous adult cell therapy products. T-MSC received FDA clearance to advance into phase 1/2a clinical trial in Multiple Sclerosis (MS). The trial was initiated in Q3 2021 and is currently ongoing. Through its research, the company has been exploring other critical diseases in the areas of: Neurology, Autoimmune, Degenerative and Rare diseases.

ImStem’s headquarters are based in Farmington, CT.